Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
uprifosbuvir
- Development stage
- Phase 2
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Uprifosbuvir (MK-3682, formerly IDX21437) is an experimental nucleotide prodrug and Hepatitis C virus (HCV) NS5B polymerase inhibitor. Originally developed by Idenix Pharmaceuticals, it was acquired by Merck & Co. in 2014 for approximately $3.85 billion to strengthen its HCV portfolio. Uprifosbuvir was designed as a pan-genotypic, once-daily oral treatment and was frequently evaluated in combination with other direct-acting antivirals, such as ruzasvir and grazoprevir (forming the combination MK-3682B). However, in 2017, Merck recorded a $2.9 billion impairment charge on the asset due to changes in the product's profile and revised expectations for pricing and market opportunity, effectively ending its development.
- Other names
- uprifosbuvirUPR
02
Targets
NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on uprifosbuvir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on uprifosbuvir.